METTL3

Across TCGA pan-cancer cohorts, METTL3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated METTL3 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher METTL3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated METTL3 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, HNSC, and COAD are the cancer types where METTL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.853	0.495	.008	34	view →
HNSC	DFS	Median	IV	0.239	0.644	.024	6	view →
COAD	OS	Median	III,IV	0.133	0.696	.019	6	view →
UCEC	DFS	Median	All	1.000	0.623	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

METTL3–BLCA (DFS)

Open the BLCA breakdown →